Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they will encourage the National Institute for Health and Care Research to rigorously evaluate existing research efforts and review how they can further prioritise and drive research investment for pancreatic cancer and other less survivable cancers.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in the fight against cancer, which is why the Department invests £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £121 million for 2022/23.
In terms of establishing targeted funding into pancreatic cancer, the NIHR funds research in response to proposals received from scientists rather than allocating funding to specific disease areas. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
The Government, through the NIHR, is committed to improving research into pancreatic cancer and cancers with the poorest survival rates by funding high quality, timely research that leads to improved outcomes for patients and the public, and makes the health and social care system more efficient, effective, and safe. Research evidence is vital for improving treatments and outcomes for people, including those with pancreatic cancer and other less survivable cancers.
In 2023, the Government awarded £2 million to new interdisciplinary research teams tackling hard to treat cancers, via the Medical Research Council, which hosted a two-day cancer sandpit strategic funding opportunity, focused on technological innovation for understanding cancers with the poorest survival rates.
The NIHR has funded seven research projects for pancreatic cancer for the period 2019 to 2023, with a total committed spend of approximately £3.6 million. The NIHR also supports the delivery of pancreatic cancer research funded by those in the charity and public sectors. For example, since 2019, the NIHR Clinical Research Network has supported over 70 pancreatic cancer-related studies.
The NIHR continues to encourage and welcome applications for research into any aspect of human health, including pancreatic cancer. All applications are assessed for funding by peer review committees. The level of research spend in a particular area is driven by factors including the quality of the proposals and their scientific potential. All applications for research into pancreatic cancer and other less survivable cancers made through open competition have been funded.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they will establish targeted funding to prioritise and drive research investment into pancreatic cancer and the other less survivable cancers.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in the fight against cancer, which is why the Department invests £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £121 million for 2022/23.
In terms of establishing targeted funding into pancreatic cancer, the NIHR funds research in response to proposals received from scientists rather than allocating funding to specific disease areas. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
The Government, through the NIHR, is committed to improving research into pancreatic cancer and cancers with the poorest survival rates by funding high quality, timely research that leads to improved outcomes for patients and the public, and makes the health and social care system more efficient, effective, and safe. Research evidence is vital for improving treatments and outcomes for people, including those with pancreatic cancer and other less survivable cancers.
In 2023, the Government awarded £2 million to new interdisciplinary research teams tackling hard to treat cancers, via the Medical Research Council, which hosted a two-day cancer sandpit strategic funding opportunity, focused on technological innovation for understanding cancers with the poorest survival rates.
The NIHR has funded seven research projects for pancreatic cancer for the period 2019 to 2023, with a total committed spend of approximately £3.6 million. The NIHR also supports the delivery of pancreatic cancer research funded by those in the charity and public sectors. For example, since 2019, the NIHR Clinical Research Network has supported over 70 pancreatic cancer-related studies.
The NIHR continues to encourage and welcome applications for research into any aspect of human health, including pancreatic cancer. All applications are assessed for funding by peer review committees. The level of research spend in a particular area is driven by factors including the quality of the proposals and their scientific potential. All applications for research into pancreatic cancer and other less survivable cancers made through open competition have been funded.
Asked by: Paulette Hamilton (Labour - Birmingham, Erdington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that all people diagnosed with pancreatic cancer who are eligible for clinical trials are able to access those trials.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Government has set out a vision for the Future of UK Clinical Research Delivery, which aims to create a patient-centred, pro-innovation, and digitally enabled clinical research environment. Key to achieving this vision is increasing participation in research to ensure that the research we support is inclusive and representative of the populations we serve.
The Department-funded National Institute for Health and Care Research (NIHR) funds research and research infrastructure which supports patients and the public to participate in high-quality research. For example, in financial year 2022/23, the NIHR Clinical Research Network supported 41 pancreatic cancer studies and recruited 1,004 participants to these studies.
In addition, the NIHR provides an online service called Be Part of Research which promotes participation in health and social care research by allowing users to search for relevant studies and register their interest. This makes it easier for people to find and take part in health and care research that is relevant to them.
When designing research studies, researchers consider inclusion and exclusion criteria carefully to ensure they are not unnecessarily excluding specific groups who would benefit from the outcome of their study. However, we are aware that inclusion and exclusion criteria can disproportionally exclude individuals from specific groups, for example older adults or pregnant women.
The Health Research Authority (HRA) is developing guidance to improve practices in this area. We are not aware that people with pancreatic cancer are routinely being excluded from studies, however, we know that sometimes people are automatically excluded from taking part, and this can be for good reasons. The guidance produced by the HRA will help researchers to consider if these people and any other groups of people may be unnecessarily excluded, and consider putting measures in place to address this.
Asked by: Paulette Hamilton (Labour - Birmingham, Erdington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions she has had with NHS England on the impact of staffing on the (a) National Cancer Patient Experience Survey programme and (b) collection of data on people with pancreatic cancer.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
We are not aware of an impact of staffing on the National Cancer Patient Experience Survey programme, or on the collection of data on people with pancreatic cancer.
The Department is working closely with NHS England to make sure we have the right workforce with the right skills, across the country. In 2023, the National Health Service published the first ever Long Term Workforce Plan, backed by over £2.4 billion of Government funding, to deliver the biggest training expansion in NHS history. Regarding cancer specifically, the number of staff in the cancer workforce has increased by 50% since 2010.
The 2022 National Cancer Patient Experience survey showed respondents’ average rating of care was 8.8 out of 10, with zero being very poor and 10 very good. 75.5% of respondents said they definitely received the right amount of support for their overall health and wellbeing from hospital staff.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to help improve pancreatic cancer outcomes in York Central constituency.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Working with NHS England, we are delivering a range of interventions that are expected to increase early diagnosis and improve outcomes for those with pancreatic cancer across England, including the York Central constituency. This includes providing a route into pancreatic cancer surveillance for those at inherited high-risk to identify lesions before they develop into cancer and diagnose cancers sooner; creating new pathways to support faster referral routes for people with non-specific symptoms that could be linked to a range of cancer types; and increasing direct access for general practitioners to diagnostic tests.
To increase early diagnosis, NHS England is implementing non-symptom specific pathways (NSS) for patients who present with non-specific symptoms, or combinations of non-specific symptoms, to receive the right tests at the right time. There are currently 113 NSS pathways live with the aim to have full national coverage by March 2024.
NHS England is also funding a new audit into pancreatic cancer, the aim of which is to provide regular and timely evidence to cancer service providers of where patterns of care in England may vary, to increase the consistency of access to treatments and to stimulate improvements in cancer treatment and outcomes for patients. The Royal College of Surgeons began work on this audit in October 2022 and a scoping exercise in consultation with key stakeholders has taken place to shape the direction of the audit. The first report is expected in October 2024.
In addition, the Getting It Right First Time team in NHS England is undertaking a deep dive into pancreatic cancer, which will highlight actions National Health Service providers need to take to improve services, as well as gathering examples of good practice to share.
To encourage people to see their general practitioner if they notice symptoms that could be cancer, NHS England runs the Help Us, Help You campaigns, which address the barriers that deter patients from accessing the National Health Service. In addition, the NHS has allocated £10 million to trial innovations that may support earlier and more efficient diagnosis, including a trial for the PinPoint blood test and a new genetic test that may be used as a liquid biopsy for those with suspected pancreatic cancer.
Asked by: John Hayes (Conservative - South Holland and The Deepings)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve pancreatic cancer diagnosis in South Holland and The Deepings constituency.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department is working with NHS England to increase diagnosis of cancer, including pancreatic cancer, across England. This includes plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis, as set out in the Elective Recovery Plan published in February 2022. In addition, the Government awarded £2.3 billion at the 2021 Spending Review to transform diagnostic services over the next three years, most of which will help increase the number of community diagnostic centres (CDCs) up to 160 by March 2025, prioritising CDCs for cancer services.
The National Health Service introduced the Faster Diagnosis Standard (FDS), which aims to ensure patients have cancer diagnosed or ruled out within 28 days of urgent suspected cancer referral from a general practice (GP) or screening services. To achieve the FDS target NHS England are implementing non symptom specific pathways (NSS) for patients who present with non-specific symptoms, or combinations of non-specific symptoms, to receive the right tests at the right time. There are currently 113 NSS pathways live, with the aim to have full national coverage by 2025.
To encourage people to see their GP if they notice symptoms that could be cancer, NHS England runs the Help Us, Help You campaigns, which address the barriers that deter patients from accessing the NHS. In addition, the NHS has allocated £10 million to trial innovations that may support earlier and more efficient diagnosis, including a trial for the PinPoint blood test and a new genetic test that may be used as a liquid biopsy for those with suspected pancreatic cancer.
Asked by: John Hayes (Conservative - South Holland and The Deepings)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with NHS England on introducing a promotional campaign to help patients recognise early symptoms of pancreatic cancer.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
My Rt hon. Friend, the Secretary of State for Health and Social Care has not had recent discussions with NHS England specifically on introducing a promotional campaign to recognise symptoms of pancreatic cancer.
NHS England is delivering a range of interventions that are expected to increase early diagnosis and improve outcomes for those with pancreatic cancer. This includes providing a route into pancreatic cancer surveillance for those at inherited high-risk to identify lesions before they develop into cancer and diagnose cancers sooner, creating new pathways to support faster referral routes for people with non-specific symptoms that could be linked to a range of cancer types, and increasing general practice direct access to diagnostic tests. A group has been formed to consider a pathway for Hepato-Pancreato-Biliary cancers, including pancreatic cancer.
On the 8 January 2024, NHS England relaunched the Help Us Help You cancer campaigns, designed to increase earlier diagnosis of cancer by reducing barriers to seeking earlier help, as well as increasing body vigilance and knowledge of key red flag symptoms. This campaign address barriers to people coming forward with suspected signs of cancer in general and is not specific to pancreatic cancer.
Asked by: Stephen Timms (Labour - East Ham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve pancreatic cancer outcomes in East Ham constituency.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England is delivering a range of interventions that are expected to increase early diagnosis and improve outcomes for those with pancreatic cancer across England, including the East Ham constituency. This includes: providing a route into pancreatic cancer surveillance for those at inherited high-risk to identify lesions before they develop into cancer and diagnose cancers sooner; creating new pathways to support faster referral routes for people with non-specific symptoms that could be linked to a range of cancer types; and increasing direct access for general practitioners to diagnostic tests.
To increase early diagnosis, NHS England are implementing non-symptom specific pathways (NSS) for patients who present with non-specific symptoms, or combinations of non-specific symptoms, to receive the right tests at the right time. There are currently 113 NSS pathways live with the aim to have full national coverage by 2025.
NHS England is also funding a new audit into pancreatic cancer, the aim of which is to provide regular and timely evidence to cancer service providers of where patterns of care in England may vary, to increase the consistency of access to treatments and to stimulate improvements in cancer treatment and outcomes for patients. The Royal College of Surgeons began work on this audit in October 2022 and a scoping exercise in consultation with key stakeholders has taken place to shape the direction of the audit. The first report is expected in October 2024.
In addition, the Getting It Right First Time team in NHS England is undertaking a deep dive into pancreatic cancer, which will highlight actions National Health Service providers need to take to improve services, as well as gathering examples of good practice to share.
Asked by: Chloe Smith (Conservative - Norwich North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of the rollout of community diagnostic centres on the time taken to diagnose less survivable cancers.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Government is taking steps through NHS England to improve outcomes for cancer patients, including those cancers mentioned by the Less Survivable Cancer Taskforce, namely lung, liver, brain, oesophageal, pancreatic and stomach. Diagnostic checks are a key part of cancer pathways and the 150 community diagnostic centres (CDCs) opened by the Government will give earlier diagnostic tests, benefitting millions of patients including those who are referred with suspected less survivable cancers. National Health Service systems have been asked to prioritise CDC capacity towards their most challenged cancer pathways, where this is clinically appropriate, and these centres have delivered over six million additional tests for all elective activity since July 2021. The CDC programme is on track to meet its target to open up to 160 CDCs by March 2025, with many due to open ahead of schedule.
In November 2022, the NHS also announced an expansion of direct access to diagnostic scans across all general practices, to help cut waiting times and speeding up cancer diagnosis, or all-clear for patients. The NHS is now looking to widen the clinical pathways for which this is offered.
Making improvements across different cancer types is critical to helping achieve the NHS Long Term Plan ambition of diagnosing 75% of patients at an early stage by 2028 and reducing inequalities in cancer survival. NHS England has commissioned new cancer clinical audits covering six cancer types, some of which are less survivable: pancreatic cancer, ovarian cancer, non-Hodgkin lymphoma, kidney cancer and primary and metastatic breast cancer. All six audits will cover care delivered in England and Wales.
Asked by: Yasmin Qureshi (Labour - Bolton South East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to reduce waiting times for treatments for (a) breast, (b) ovarian and (c) prostate cancer.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Reducing waiting times for treatments of all types of cancer is a priority for the Government, as is increasing early cancer diagnosis as this is a key contributor to reducing cancer health inequalities. We are expanding capacity through our community diagnostic centres (CDCs) supported by £2.3 billion of capital funding with 150 CDCs currently operational and having delivered over six million additional tests, checks and scans including vital cancer checks since January 2021.
The planned Major Conditions Strategy will look at the early diagnosis and treatment of cancer and will consider a wide range of interventions and enablers to improve outcomes and experience for a range of cancer patients, including those less survivable cancers.
NHS England has commissioned six cancer clinical audits which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments and help stimulate improvements in cancer treatments and outcomes for patients, including ovarian cancer, pancreatic cancer, non-Hodgkin lymphoma, kidney cancer and primary and metastatic breast cancer. The Royal College of Surgeons began work on this audit in October 2022, and the first outcomes expected in September 2024.